About
Osmol Therapeutics is developing OSM-0205, a drug candidate that aims to prevent chemotherapy-induced peripheral neuropathy (CIPN) and chemotherapy-induced cognitive impairment (CICI) in cancer patients undergoing taxane-based chemotherapy.
Explore Osmol Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.